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Abstract
Breast conserving surgery (BCS) is now the standard of care for the majority of women with early stage breast cancer. There is a finite rate 
of ipsilateral breast tumour recurrence (IBTR) for breast conserving therapy (BCT) with annual rates of less than 1% for specialist breast 
practices.
There has been recent consensus on the definition of an adequate resection margin for both invasive and noninvasive breast cancer 
treated with BCS, although some variation in margin policy persists with definitions of ‘no tumour at ink’, 1 and 2 mm margin mandates.
Despite the development of methods for intraoperative assessment of margins, up to 20% of patients require further surgery (cavity 
re-excision or completion mastectomy) to achieve clear surgical margins.
In the past decade, several novel technologies for intraoperative margin assessment have been explored with the aim of reducing rates of 
re-operation and its attendant patient anxiety, inconvenience and additional cost. Ongoing studies are addressing the safety, feasibility and 
cost-effectiveness of these novel technologies relative to methods in routine clinical usage.
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Introduction
Breast conserving surgery (BCS) has become the preferred standard of care for surgical management of women with early stage breast 
cancer over the past 30 years (NIH Consensus Conference 1991). Successful BCS entails excision of the tumour with an adequate amount 
of surrounding normal breast parenchyma, such that negative resection margins are obtained. Longer term follow-up data from several 
prospective randomised controlled trials have demonstrated survival equivalence for BCS combined with breast radiotherapy, when com-
pared with radical or modified radical mastectomy [1–4]. Introduction of breast conserving therapy (BCT) has coincided with instigation of 
widespread mammographic screening, smaller tumour size at presentation and improvements in adjuvant therapies (radiotherapy, che-
motherapy and hormonal/biological therapies). There is a finite rate of ipsilateral breast tumour recurrence (IBTR) for patients undergoing 
BCT, with current estimates supporting an annual rate of less than 1% for specialist breast practices and corresponding rates of between 
3.5% and 6.5% at ten years [5]. Systemic chemo-hormonal therapies reduce rates of IBTR by approximately one-third, whilst anti-HER2 
therapies can lead to halving of local in-breast recurrence.
Despite these dramatic improvements in rates of local control following BCT, between 20% and 30% of patients with either invasive or 
noninvasive disease typically require re-operation following initial BCS (be this cavity re-excision or mastectomy). These high rates of 
re-excision are often prompted by a component of ductal carcinoma in situ (DCIS), which usually has no clinical correlate and may be 
underestimated in its extent radiologically.
Definition of negative margins 
Until recently, there has been much variation in opinion amongst surgeons and radiation oncologists as to what constitutes an adequate or 
‘negative’ surgical margin after BCS. Surgical margin status is considered as a major predictor of IBTR, but no consensus on what constitutes 
an ‘adequate’ width of surgical margin existed until the dual publication of an international consensus statement in 2014 [6]. Breast conserva-
tion surgery represents a balance between oncological mandates and cosmetic outcomes with surgeons aiming to excise tumour with ‘nega-
tive’ margins and acceptable cosmesis; the closer ink is to tumour, the narrower are the margins and a positive margin is associated with ink 
on cancer cells (Figure 1). Singletary [7] published one of the first major reviews of surgical margins at the beginning of the millennium and 
concluded that it was unacceptable to have tumour at the margin, as positive margins were associated with a doubling of rates of IBTR com-
pared with nonpositive margins. However, there was no correlation between the width of the surgical margin and rates of IBTR. A large meta-
analysis of 21 studies involving 14,571 patients with invasive breast cancer was published by Houssami et al [8] in 2010. This confirmed that 
the odds ratio for local recurrence was 2.42 [p < 0.001] for positive margins (i.e., tumour at ink). Of note, there was no statistically significant 
difference in rates of local recurrence between individual margin widths of >1, >2 or >5 mm. In particular, a margin width of 2 or 5 mm was 
not necessarily better than a narrower margin of 1 mm when results were adjusted for follow-up time and receipt of a radiation therapy boost 
and endocrine therapy. A 1 mm margin was therefore deemed to be adequate, provided patients received optimal adjuvant therapy [8]. An 
updated meta-analysis by the same authors involving involving 28,162 patients with invasive breast cancer (IBTR = 1506) employed random-
effects logistic meta-regression, defined as a relative category of ‘close’ with cancer cells between a defined distance (negative margin) and 
the surgical resection margins (no tumour at ink) [9]. The odds ratio for IBTR was 1.98 [p < 0.001] for positive or close margins compared with 
negative margins and 2.44 [p < 0.0001] for positive versus negative margins. There was no statistical evidence that increase in margin width 
from ‘no tumour at ink’ to 1, 2 or 5 mm influenced the odds of local recurrence with adjustment for follow-up time. Nonetheless, it should be 
noted that this meta-analysis contained a few cases permitting direct comparison of a 1 mm margin versus ‘no tumour at ink’. For this reason 
and based on the results of the initial meta-analysis [8], the Association of Breast Surgery in the United Kingdom have adopted 1 mm as the 
minimum margin mandate for invasive disease (with or without admixed DCIS) and also for pure forms of DCIS. By contrast, the international 
consensus statement emphasised that an adequate margin exists when tumour is not touching ink, and this has been widely adopted in the 
past couple of years by more than two-thirds of surgeons in the United States. Indeed, this minimisation of margin mandate has led to a reduc-
tion in rates of re-excision at the Memorial Sloan-Kettering Cancer Centre from 21% to 15% [10]. (Table 1)
Intraoperative specimen imaging
Notwithstanding the above rates of re-excision and re-operation, following routine BCS for both palpable and impalpable lesions 
remains high and this has spurred efforts to develop reliable intraoperative assessment tools which can provide a timely indication of 
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whether re-excision of a cavity margin is indicated at the time of primary surgery. More conventional imaging methods of specimen 
radiography and intraoperative ultrasound (IOUS) share the limitation of detecting DCIS and microscopic margin involvement, whilst 
pathological assessment with frozen section and touch imprint cytology is labour intensive. Many surgeons perform intraoperative 
radiological assessment of impalpable (and sometime palpable) lesions using portable X-ray devices such as the Faxitron; McCornick 
et al [11] found that use of intraoperative specimen radiography more than halved rates of positive margins (reduced from 12% to 5%) 
whilst Layfield et al [12] reported that use of intraoperative specimen radiography for palpable breast cancer led to a reduction in the 
mean specimen weight without increasing re-excision rates and was associated with improved cosmesis. In a prospective study involv-
ing 170 cases of both palpable and impalpable lesions, margin status was assessed systematically with intraoperative specimen radi-
ography, using a dedicated intraoperative X-ray device (Faxitron MX20). Margins were evaluable in 91.2% of cases and were assessed 
according to the histological subtype; thus, attaining a 10 mm margin on Faxitron led to negative margins in 98.5% of invasive ductal 
carcinomas, 90% of invasive lobular carcinomas and 78.5% of DCIS cases with an overall margin positivity rate of 6.5% when intraop-
erative specimen radiography was employed. (Figure 2) The correspondingly high negative margin rate (93.5%) can potentially lead to 
savings of time and costs. 
Figure 1. Macroscopic assessment and inking breast wide local excision specimen.
Table 1. Consensus guidelines and policies for margin mandates.
Invasive cancer Pure DCIS
ABS UK* 1 mm 1 mm
SSO-ASTRO** No tumour at ink 2 mm
*Association of Breast Surgery United Kingdom 
**Society of Surgical Oncology and American Society of Radiation 
Oncology
Figure 2. Faxitron: intraoperative assessment of margins in BCS.
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Another intraoperative imaging modality for reducing rates of margin positivity at initial surgery is IOUS, which can be performed by sur-
geons who are increasingly ultrasound competent. In a prospective observational cohort study, Karalik et al [13] undertook BCS guided 
by either ultrasound (n = 84) or palpation (n = 80) amongst two groups of women matched for demographic and tumour characteristics. 
Use of IOUS reduced the rate of re-excision from 17% for palpation-guided lumpectomy to only 6% with IOUS. (p = 0.03). Moreover, the 
volume of tissue resected in the palpation-guided group was significantly higher despite comparable tumour size (p = 0.048) and equivalent 
cosmetic outcomes.
The COBALT study is a prospective multicentre trial which addressed the hypothesis that use of IOUS for wide local excision of palpable 
breast cancers could potentially spare healthy tissue and improve both surgical margin status and cosmesis. The trial was conducted in 
the Netherlands, but accrued a relatively small number of patients in relation to the number of centres and participating surgeons. Notwith-
standing this comment, the trial had 80% power to detect an 18% reduction in the re-excision rates. A total of 134 patients with palpable 
early stage primary invasive breast cancer (T1-2, N0-1) were randomised to either ultrasound-guided surgery (USS) or palpation-guided 
surgery (PGS). Some patients had invasive tumour associated with DCIS, which influenced rates of margin positivity. Nonetheless, use of 
ultrasound significantly increased the negative margin rate from 83% (PGS) to 94% (USS) (p = 0.03). Moreover, specimen volumes at first 
excision were significantly lower for the USS group compared with the PGS group (p = 0.048). The trial contained a quality-of-life sub-study 
and also examined cosmetic outcomes [14]. 
Another familiar imaging modality is MRI which can be used for specimen radiography; however, this methodology within the context of 
surgical excision specimens is impractical, time consuming and unlikely to be cost-effective in any managed healthcare system. 
Routine cavity shaves and intraoperative margin pathology
Several observational studies have shown a significant reduction in rates of re-excision when additional tissue is routinely removed from 
all margins of the surgical cavity (x 6) [15, 16]. However, some of these studies report adverse effects on cosmesis, and a report by 
Coopey et al [17] found that routine cavity shaves do not impact upon rates of re-excision and indeed the volume of tissue excised in the 
main specimen was less for the cavity shave group, suggesting a conscious modification of surgical technique when immediate cavity 
re-excision was anticipated. More recently, a randomised trial involving 235 patients with stage 0–III breast cancer undergoing BCS with 
or without routine cavity shaves was published in the New England Journal of Medicine [18]. Randomisation to routine cavity shaves led 
to a statistically significant reduction in the margin positivity rate (19% versus 34%; p = 0.01) compared with equivalent rates prior to 
randomisation (36% shave group; 34% non-shave group). This was associated with a commensurate reduction in rates of re-operation to 
achieve negative margins for the shave compared with non-shave groups (10% versus 21%), respectively, p = 0.02). Interestingly, these 
authors found no statistically significant difference in the total specimen weight between the two groups. A comparison of different intraop-
erative margin management techniques was reported by Bolger et al [19], who examined three approaches – routine cavity shave margins 
(n = 70), macroscopic assessment of margins (MMA) (n = 68) and no formal margin assessment (n = 50). Routine cavity shaves with a 
minimum thickness of 1 cm were taken from four surfaces and MMA involved the pathologist examining the specimen for assessment 
of margin status. The distance of tumour from each radial margin (medial, lateral, superior and inferior) was measured and if less than 
5 mm, this prompted re-excision of that margin. The remaining group underwent re-excision at the discretion of the operating surgeon. 
Comparison of the two groups with formal assessment of margins revealed a re-excision rate of 25% compared with 34% for the group 
without formal evaluation of margins and a statistically significant reduction in the chance of residual disease following the initial surgical 
procedure (p = 0.02). Formal assessment did not lead to any notable prolongation of operating time.
Both frozen section and touch imprint cytology are time consuming and require input from a pathologist; in terms of diagnostic accuracy, fro-
zen section was found on meta-analysis to have a pooled sensitivity of 0.86 (95% CI 0.78–0.91) and a specificity of 0.96 (95% CI 0.92–0.98), 
but with significant heterogeneity between studies. By comparison, cytology had a pooled sensitivity of 0.91 (95% CI 0.71–0.97) and a speci-
ficity of 0.95 (95% CI 0.90–0.98). Once again, there was significant heterogeneity between studies with an I2 exceeding 90% [20]. In terms of 
comparative performance, these tissue-based techniques are most accurate for intraoperative margin assessment, but have very poor uptake 
in routine clinical practice. This most likely relates to the logistical issues of slow turnaround times, disruption of operating lists and availability 
Re
vi
ew
 5 www.ecancer.org
ecancer 2018, 12:795
of pathology staff [20]. Use of frozen section in American practice is reported to reduce rates of re-operation from 13.2% to 3.6%, although it 
remains unclear what proportion of practices in the United States employs methods for intraoperative assessment of margins [20].
Novel technologies for margin assessment
In recent years, several novel technologies have been explored for assessment of margin status in light of the limitations of the above 
methods, especially for impalpable lesions and DCIS. It is essential that these newer technologies have similar diagnostic accuracy to 
conventional methods involving pathological examination of tissue. However, they must also offer advantages in terms of turnover times, 
practicality and cost before introduction into routine clinical practice (especially in a managed healthcare system).
Some of these can detect microscopic malignancy at the edges of the surgical specimen and therefore have potential to reduce the margin 
positivity and rates of re-excision to a much greater degree than conventional methods for intraoperative specimen radiography. These 
newer methods for assessment of surgical margins generally involve some form of electromagnetic waves which can penetrate the surface 
of the specimen to a variable depth and can distinguish between benign and malignant tissue in real time. Interestingly, recent reduction in 
the margin mandate for both invasive and noninvasive cancer favours these emergent technologies which have limited tissue penetrance 
and are ideally suited for detection of cancer cells within 1 mm of the inked specimen margin [20].
MarginProbe
One such technology is the MarginProbe device (Dune Medical Services Limited, Caesarea, Israel) based on reflection of radiofrequency 
waves that measure local electrical properties of breast tissue within the radiofrequency range. The device creates an electrical signature 
of tissues that is dependent on the membrane potential, nuclear morphology and intercellular contact. The device also takes account of dif-
ferences in vascularity, and collectively these factors permit distinction between malignant and benign/normal tissue. (Figure 3) The overall 
sensitivity for detection of malignancy is 70–100%, but specificity is slightly lower at 70–87% [21]. Of note, these performance parameters are 
similar for invasive carcinoma (ductal and lobular) and DCIS [22]. The MarginProbe has been designed as an adjunct to routine surgical meth-
ods, the hand-held device is convenient to use and the probe has a 7 mm footprint which is employed to take between five and eight measure-
ments from each of six surfaces of the excised specimen (previously defined with an ink pen). A positive reading indicates tumour cells present 
within 1 mm of the resection margin. Any positive reading is interpreted as a positive margin and re-excision of that margin is undertaken.
Figure 3. Marginprobe: tissue assessment.
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Early studies with MarginProbe randomised patients to routine surgical technique (including re-excision prompted by palpation or specimen 
radiograph) or usual technique combined with MarginProbe. These have revealed reductions in rates of re-excision from 25% to 12% for 
the device arm with no differences in the cosmetic outcomes [23]. The MarginProbe device can therefore increase the ability of surgeons 
to identify and excise positive margins at the time of surgery, without employing pathological methods for intraoperative assessment such 
as frozen section or cytology. In consequence, MarginProbe can reduce rates of re-operation for the benefit of patients and the healthcare 
system [24].
ClearEdge™
Another related technology is the ClearEdge™ (CE) imaging device which measures tissue-specific electrical properties. It is also a conve-
nient hand-held portable imaging device which uses bioimpedance spectroscopy to detect both extracellular and intracellular variations in 
tissue dielectric properties, enabling identification of abnormal tissue containing pathological changes of invasive cancer, DCIS, lobular car-
cinoma in-situ (LCIS) and atypical proliferations such as atypical ductal and lobular hyperplasia. The specificity is slightly compromised by 
detection of increased cellularity associated with inflammation. The device assesses the local dielectric properties of tissues when directly 
in contact. A preliminary study was done under the auspices of Michael Dixon in the Edinburgh Breast Unit, which enlisted nine surgeons 
and was conducted in two phases. Phase-1 (58 patients) was designed to validate the safety and accuracy of the CE imaging device when 
used on excised specimens ex vivo. This would indicate the potential for the device to reduce rates of re-excision, which was specifically 
addressed in Phase-2 of the study, whereby the device was used intraoperatively in 63 patients in an attempt to reduce the need for re-
operation to achieve negative margins. The performance of the CE imaging device was similar for the two phases of the study and readouts 
from the device were compared with permanent section pathology (sensitivity [84.3% versus 87.3%]), specificity (81.9% versus 75.6%), 
positive predictive value (67.2% versus 63.6%) and negative predictive value (92.2% versus 92.4%). Furthermore, the false positive and 
negative rates were comparable for the CE device and permanent pathology. There was a learning curve amongst the surgeons and it was 
commented by Dixon et al [25] that had all images been interpreted appropriately and some re-excised margins identified as CE abnormal 
in Phase-2 of the study, the rate of re-excision would have been 8% (overall rate of excision 17% for all patients).
Intelligent knife
An intriguing technology is the ‘intelligent knife’, which analyses the electrosurgical plume of diathermy smoke to determine the structural 
lipid profile of tissue. This is based on rapid evaporative ionisation mass spectrometry (REIMS) with online chemical analysis of the elec-
trosurgical aerosol. Use of electrical diathermy in the cutting or coagulation mode triggers a cellular explosion from heat dissipation with 
release of cellular product into a gas phase. Chemical analysis using both cutting and coagulation modality was performed on a normal 
and tumour breast tissue and validation spectra correlated with tissue microscopic tissue histology. The so-called i-knife has now been 
optimised for real-time intraoperative analysis of breast tissue and yields high rates of sensitivity and specificity. REIMS shows promis-
ing results for detection of positive resection margins intraoperatively (100%) and has a sensitivity of 77.3%. A false positive margin was 
recorded in only 0.5% of the total dissection time calculated as 69/14,023 spectra [26]. Further validation studies will clarify the performance 
characteristics and in particular determine the accuracy for intraoperative margin assessment [27].
Conclusions
Several emergent technologies exist which can potentially improve intraoperative margin assessment and reduce rates of re-excision, but 
further technological developments are required to augment image processing and facilitate routine clinical usage. Moreover, these will 
need to compare favourably with direct tissue-based methods, such as frozen section and cytology, which are notably more sensitive and 
specific than most other methods of margin assessment. Nonetheless, issues such as time, cost and reliability must be factored into any 
final evaluation and devices such as MarginProbe and ClearEdge may find clinical utility in routine daily practice where surgical workloads 
are substantial.
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